Biotechs put assets up for sale and on the shelf in quarterly pipeline clear-outs

Biotech earnings season has delivered a deck of dead and deprioritized assets, with Xilio Therapeutics, Protagonist Therapeutics, Arbutus Biopharma and Aptinyx all deciding they have better uses for their cash.